Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 placebo-controlled trial of VP-315 in patients with Basal Cell Carcinoma

Next Previous
Trial Profile

A phase 3 placebo-controlled trial of VP-315 in patients with Basal Cell Carcinoma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxotemitide (Primary)
  • Indications Basal cell cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 11 Dec 2025 New trial record
  • 14 Nov 2025 According to a Verrica Pharmaceuticals media releaseThe FDA confirmed alignment with the Companys plan for the Phase 3 program to encompass two placebo-controlled Phase 3 studies with approximately 100 subjects each and a primary endpoint of complete clearance as assessed at week 14. Based on the discussion with the FDA, the Company expects these studies will be adequate to support a New Drug Application (NDA) filing, with long-term follow-up studies to be conducted as post-approval commitments.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top